COVID-19 seems to skew Abbott heart failure monitor study results

A clinical trial evaluating the effectiveness of Abbott Laboratories' implantable heart failure monitor in an expanded patient population missed its primary endpoint, but a pre-COVID-19 impact analysis showed a potential benefit in reducing hospitalizations for patients with mild heart failure symptoms, according to results presented in The Lancet.